LB Pharmaceuticals names Kaya Pai Panandiker as CCO

LB Pharmaceuticals (Nasdaq: LBRX), a US clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as chief commercial officer (CCO).

Ms Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and in launching and scaling global brands.

“We are very pleased to welcome Kaya to LB Pharmaceuticals,” said Heather Turner, chief executive of LB, adding: “Her deep experience leading neuroscience brands and preparing multiple successful launches will be instrumental as we advance LB-102 toward registration and commercialization. Kaya’s proven ability to translate science into patient and market impact will be key to maximizing the potential of LB-102 and driving long-term value creation.”